Company Overview & Context
Soleno Therapeutics (NASDAQ: SLNO) is a clinical-stage biopharmaceutical company that achieved a transformational year in 2025 by launching its first product, VYKAT™ XR (diazoxide choline extended-release) for Prader-Willi syndrome (PWS). PWS is a rare genetic disorder, and VYKAT XR became the first FDA-approved therapy to treat hyperphagia (insatiable appetite) in PWS patients (www.globenewswire.com). The drug was approved on March 26, 2025 and launched in the U.S. shortly thereafter, driving Soleno’s rapid growth from zero revenue to profitability by Q3 2025 (www.globenewswire.com) (www.globenewswire.com). However, alongside this success, Soleno now faces investor lawsuits alleging securities fraud, with a lead plaintiff deadline of May 5, 2026 for affected shareholders (natlawreview.com). The legal action claims Soleno misled investors about VYKAT’s safety profile, and “when the true details entered the market” the stock price plummeted (www.globenewswire.com) (natlawreview.com). In this report, we delve into Soleno’s fundamentals – dividend policy, financial leverage, cash flow coverage, valuation, and key risks – to equip investors with a clear picture of the company’s position amid the ongoing scrutiny.
Dividend Policy & AFFO/FFO
Dividend History: Soleno does not pay any dividends. The company has never declared a dividend, which is typical for development-stage biotechs that prioritize reinvestment over shareholder payouts (www.alphaspread.com). With Soleno only recently reaching its first profitable quarter, all earnings are being reinvested in the business and new development rather than distributed to shareholders. As a result, dividend yield is 0% and there is no track record of past dividends or share buybacks beyond 2025’s one-time program (discussed below).
AFFO/FFO Metrics: Metrics like Funds From Operations (FFO) or Adjusted FFO (AFFO) are used mainly for real estate trusts or companies with stable operating cash flows – they are not applicable to Soleno. As a biotech, Soleno’s cash flows have historically been negative, turning positive only after its product launch in mid-2025. Instead of FFO, investors focus on Soleno’s operating cash flow and earnings from drug sales. In 2025, Soleno generated ~$48.7 million of cash from operations in Q4 alone (www.globenewswire.com), reflecting strong initial sales of VYKAT XR. The company’s free cash flow is expected to remain positive so long as VYKAT XR’s uptake continues, but traditional FFO/AFFO metrics aren’t relevant in evaluating Soleno’s performance.
Want the exact ticker tied to Project Trillionaire?
Inside: step-by-step instructions to take a $100 position in the company acting as SpaceX’s silent partner — plus the ticker and timing tips.
Leverage and Debt Maturities
Soleno’s balance sheet is fortified with cash and carries modest debt. In late 2024, the company entered a $200 million loan facility with Oxford Finance, drawing an initial $50 million upfront (investors.soleno.life). The remaining $150 million is available in future tranches contingent on milestones (FDA approval of VYKAT XR – which has been achieved – plus commercial targets, and an additional $50 million at lender’s consent) (investors.soleno.life). Key terms of the Oxford loan are highly favorable to Soleno’s near-term liquidity: an interest-only period of 48 months followed by a 12-month amortization, for an initial 5-year term (extendable by 1 year if certain sales milestones are met by September 2026) (investors.soleno.life). The loan carries a floating interest rate of 1-month SOFR + 5.5% (~10–11% currently) (investors.soleno.life).
As of year-end 2025, Soleno had $506.1 million in cash and equivalents on hand (www.globenewswire.com), vastly exceeding the $50 million debt principal – effectively putting the company in a net cash position. The debt-to-equity ratio stands at only ~0.11 (finviz.com), reflecting very low leverage relative to its equity base. In July 2025, Soleno even raised an additional $230 million through an equity offering (www.globenewswire.com), bolstering its cash reserves to fund commercialization and pipeline expansion. Notably, management used $100 million of its cash in Q4 2025 for an accelerated share repurchase program, signaling confidence in the company’s value (www.biospace.com). This buyback reduced shares outstanding (a benefit to remaining shareholders) but also indicates that Soleno had surplus capital beyond its operational needs.
- Predicted IPO date: March 26, 2026
- Options: ARKVX, private fund access code, bonus reports
- Only 500 access codes — first come, first served
Debt Maturities: With the Oxford loan not requiring principal repayments until at least late 2028, Soleno faces no near-term refinancing risk. The loan’s full maturity will occur in December 2029 (or 2030 if extended) – giving Soleno several years of runway to establish its commercial footing before any debt repayment comes due (investors.soleno.life). There are no other significant long-term liabilities reported in its SEC filings beyond typical lease obligations. Overall, Soleno’s leverage profile is low-risk at present: ample cash, minimal debt, and a long-dated maturity schedule.
Coverage and Cash Flow
Given its strong cash position and newly positive cash flows, Soleno has no issues covering its financial obligations. The Oxford loan’s interest expense is estimated around $5–6 million annually at current rates, which is easily covered by Soleno’s operating cash flow generation (e.g. $48.7 million cash from operations in Q4 2025 alone) (www.globenewswire.com). The company’s interest coverage ratio – EBIT relative to interest paid – is very high. For example, in Q4 2025 Soleno had roughly $43 million in net income (www.globenewswire.com), whereas interest costs on $50 million of debt (at ~10% annual) would be only ~$1.25 million per quarter. This implies an interest coverage well above 30× for that quarter. Even on a full-year basis, Soleno’s 2025 EBIT was ~$29 million (net income $20.9M plus ~$8M of non-cash expenses) against ~$3–4 million of annual interest, still a double-digit coverage ratio. Thus, debt service is comfortably covered by earnings and cash reserves.
Importantly, Soleno has no dividend or preferred stock obligations, so there are no coverage considerations regarding payouts. All cash can be reinvested into growth or used opportunistically (as seen with the share buyback). The operational cash burn that characterized Soleno’s pre-approval years has flipped – in 2025 the company achieved positive cash flow, meaning internal cash generation can now fund ongoing expenses (www.biospace.com). However, investors should monitor patient adoption trends closely: if sales were to stagnate or decline, Soleno could revert to burning cash (especially if R&D spending ramps up for new indications). At present, though, coverage ratios and liquidity appear very robust.
Valuation and Comparables
Soleno’s stock experienced a meteoric rise in 2024–2025 as VYKAT XR progressed through approval and launch – delivering a +3000% return over 3 years (finviz.com). As of late 2025, Soleno’s share price hovered around $45–$50, equating to a market capitalization of roughly $2.5 billion (finviz.com). Net of its hefty cash reserves, the enterprise value (EV) was about $2.0 billion (finviz.com). How does this valuation stack up against the company’s financial performance?
– Price-to-Sales (P/S): In the nine months of 2025 following launch, Soleno generated $190.4 million in revenue (www.globenewswire.com). This implies a trailing EV/Sales of ~10.7× ($2.04B EV / $190M sales). While this multiple is high in absolute terms, it’s not unusual for a high-growth orphan drug company in its first year of commercialization. If VYKAT’s sales continue climbing (Q4 2025 revenue grew ~40% sequentially over Q3 (www.globenewswire.com)), the forward EV/Sales will drop quickly – for instance, based on preliminary Q4 results, the annualized run-rate was ~$368 million (Q4’s $92M 4), giving an EV/Sales forward closer to ~5.5×.
– Earnings Multiple: Soleno reported a full-year 2025 net profit of $20.9 million (www.globenewswire.com), which on the surface yields a steep trailing P/E of ~120×. However, that figure is not very meaningful, as 2025 included only a partial year of sales and heavy launch expenses. The company’s earnings ramped up each quarter (Q4 alone delivered $43.3 M in net income) (www.globenewswire.com). Looking ahead, analysts expect a dramatic jump in 2026 earnings, with consensus EPS around $4.11, implying net income on the order of ~$200 million. At the current share price, this gives a forward P/E of ~11 (finviz.com), which is comparatively low for a biotech with a novel marketed product. Such a discounted multiple suggests that the market has baked in a healthy dose of skepticism (likely due to the safety and legal clouds discussed below).
– Peer Comparison: Direct comparables are scarce, since Soleno is the first mover in PWS treatment. One way to benchmark is against other rare-disease drug launches. Companies launching orphan drugs often trade at high revenue multiples due to limited competition and pricing power. Soleno’s ~10× trailing P/S is in line with many early-stage commercial biotechs, and its ~11× forward P/E is actually lower than most (reflecting Soleno’s unique position of already generating profit and the Street’s cautious outlook). For context, multiple investment banks initiated coverage of SLNO in 2025 with aggressive price targets – e.g. Goldman Sachs at $125, Wells Fargo $123, and others in the $75–$110 range (finviz.com). These targets (some more than double the current price) were based on optimistic sales projections and the expectation that Soleno’s market penetration in PWS would continue to expand rapidly. The bullish analysts essentially view Soleno’s current valuation as undemanding if VYKAT XR’s uptake and safety profile hold up. On the other hand, the stock’s substantial short interest (~19% of float) indicates that many investors are betting on difficulties ahead (finviz.com). This divergence in outlook (Wall Street analysts vs. short sellers) underscores the uncertainty surrounding Soleno’s true fair value.
In summary, Soleno’s valuation reflects both high growth potential and significant perceived risk. By traditional metrics, the company could appear undervalued (given its rare disease franchise and cash-rich balance sheet) or overvalued (if one doubts the longevity of its current sales trajectory). It essentially trades as a “story stock” driven by clinical and commercial milestones, rather than steady-state fundamentals.
Risks and Challenges
Investors in Soleno should be aware of several key risks that could adversely impact the company’s performance and stock price:
– Safety & Regulatory Risk: Soleno is heavily dependent on a single product, VYKAT XR, and its safety profile is under scrutiny. The drug’s mechanism (diazoxide, a KATP channel modulator) can cause significant side effects like fluid retention and edema, which may lead to serious complications (www.globenewswire.com). In fact, the current lawsuit alleges Soleno “downplayed…evidence of safety concerns” in the DCCR trials – including issues of excess fluid retention in patients – and that DCCR poses greater safety risks than the company disclosed (www.globenewswire.com). If new or worse safety issues emerge (e.g. incidence of heart failure, as seen in one post-market case (natlawreview.com)), regulators could impose additional warnings, a Risk Evaluation and Mitigation Strategy (REMS), or even suspend marketing. The FDA approval presumably came with an understanding of known risks, but any adverse regulatory action in light of safety problems would be devastating (www.globenewswire.com). Soleno must also carefully monitor patients and report outcomes; failure to be transparent could invite FDA sanctions or limit physician adoption.
– Legal and Reputational Risk: The securities class action now facing Soleno (and related shareholder “investigations” by various law firms) is itself a risk. While such lawsuits are not uncommon after a stock plunge, they can distract management and potentially lead to settlements or judgments that cost money and hurt reputation. Here, the suit claims Soleno’s executives made false or misleading statements about DCCR’s safety, and that investors suffered losses when the truth came out (www.globenewswire.com) (www.globenewswire.com). This references the events of late 2025: a short-seller report by Scorpion Capital in August 2025 accused Soleno of concealing safety issues (and noted the existence of cheaper generic alternatives) (natlawreview.com). Soleno’s CEO acknowledged on November 4, 2025 that the Scorpion report had caused a “disruption” in the drug’s launch, correlating with fewer new patient starts and increased discontinuations in the wake of its publication (natlawreview.com). That same day, Scorpion Capital highlighted a case of a patient who suffered congestive heart failure after starting DCCR, fueling fears in the PWS community (natlawreview.com). When this news broke, Soleno’s stock plunged ~27% in one day (from ~$64 to $47) (natlawreview.com). The entire episode suggests a vulnerability: negative publicity (whether from short-sellers, patient advocacy groups, or media) can sharply affect Soleno’s standing. Ongoing litigation will keep these safety allegations in the spotlight. Even if Soleno prevails in court or settles without admitting fault, management’s credibility has been called into question – making investors and physicians warier of the company’s claims.
– Commercial Execution Risk: Although Soleno’s initial sales have been impressive, it is still early in commercialization. The company grabbed ~12% of the U.S. addressable PWS market in 9 months (www.globenewswire.com), which means the majority of patients are not yet on therapy. It will become increasingly challenging to sustain the torrid growth rate: after the pool of early adopters (often the most motivated patients/families) is tapped, Soleno might see sales growth decelerate. Factors that could impede further uptake include: physician caution about side effects, patients discontinuing therapy, and payer barriers (while 185 million lives are covered by insurance, that’s ~60% of total – Soleno still needs to secure coverage for the remaining insurers) (www.biospace.com) (www.biospace.com). Notably, by Q4 2025 the discontinuation rate due to adverse events had reached ~12% of patients (www.biospace.com). If one in eight patients cannot tolerate the drug, this puts a natural cap on long-term adoption unless mitigation strategies (dose management, diuretics for edema, etc.) improve retention. Prescription trends should be watched closely: Soleno reported 207 new patient start forms in Q4, down from 397 in Q3 (www.globenewswire.com) (www.biospace.com) – this might be seasonal variability or an early sign of a plateau. Any shortfall in expected growth (versus bullish analyst projections) could hurt the stock.
– Single-Product Dependence: Soleno’s entire valuation hinges on VYKAT XR’s success. The company currently has no other revenue-generating products to diversify risk. While it plans to explore DCCR in additional rare diseases, those are in nascent stages (www.globenewswire.com). This concentration risk means Soleno is highly vulnerable to any event that disrupts VYKAT XR’s trajectory – such as a manufacturing issue, regulatory delay in new markets, or a competing therapy emerging. Competition might not be imminent (Soleno enjoys orphan drug exclusivity in PWS for 7 years in the U.S.), but the barrier to entry isn’t insurmountable in the long run. DCCR is a reformulation of a decades-old molecule (diazoxide); if the PWS market proves lucrative, generic drug manufacturers or other biotechs could attempt alternative formulations or combination therapies. The Scorpion report pointed out that generic diazoxide (immediate-release) is available (natlawreview.com) – conceivably, doctors could prescribe it off-label for PWS, though with less convenience and potentially more side effects than VYKAT’s controlled-release. Furthermore, after Soleno’s exclusivity and patents expire (likely in the early 2030s), generic competition could erode pricing power. Investors must recognize that Soleno lacks a portfolio – its fortunes rise and fall with one asset.
– Financial and Market Risks: On the financial side, Soleno is in a strong position now (over $500 M cash, profitable operations), but the biotech sector is volatile. High short interest (nearly 19% of the float shorted) indicates that many traders are positioning for the stock to fall (finviz.com). This can increase share price volatility and the risk of a negative feedback loop (e.g. bad news can be magnified as shorts pile on). Additionally, while Soleno has cash for now, ambitious expansion – such as international launches or new trials – could consume resources quickly. If, for any reason, sales falter or major expenses arise, the company might need to raise capital again in a less favorable climate. Macro factors like interest rates (which affect the cost of capital and biotech valuations) and healthcare policy (e.g. drug pricing debates) also loom as background risks.
Finally, it’s worth noting that insider and institutional behavior can be a soft risk factor. So far, Soleno insiders have not shown alarming stock sale activity (no major insider dumping has been reported – insider ownership changes are minimal (finviz.com)). In fact, the mid-2025 equity raise was likely driven by institutional demand given the excitement around approval. However, retail investors should be mindful that large institutions own over 100% of the float (due to share lending and recent offerings) (finviz.com), meaning the stock’s fate could be swayed by a few key holders. Any shift in sentiment from these holders – or an exit by one of Soleno’s major backers – would present a risk to the share price.
Red Flags for Investors
In light of the above risks, certain red flags stand out that current or prospective SLNO investors should not ignore:
– Discrepancy in Safety Messaging: There is a notable gap between Soleno’s public optimism on VYKAT XR’s safety and the reality of its side effects. Management has repeatedly touted the drug’s “favorable efficacy and safety profile” (www.globenewswire.com), emphasizing that some patients have been on DCCR for years. Yet by end of 2025, Soleno disclosed a significant 12% adverse-event discontinuation rate among patients (www.biospace.com), and real-world reports surfaced of serious outcomes like heart failure (natlawreview.com). The drug’s label itself carries a warning for “Risk of Fluid Overload – Edema, including severe reactions associated with fluid overload, has been reported” (www.globenewswire.com). This contrast raises a red flag about management’s transparency. Were the early communications painting too rosy a picture? The class action alleges exactly that – i.e. that Soleno misrepresented safety data to investors (www.globenewswire.com). Investors should be cautious if a company’s narrative appears to downplay known risks.
– Short-Seller Allegations (Scorpion Capital): The involvement of Scorpion Capital, an activist short seller known for deep-dive research, is a red flag that deserves attention. Scorpion’s August 2025 report (and continued public criticism) suggested that Soleno might be overstating its drug’s prospects and ignoring pitfalls (natlawreview.com). Specifically, Scorpion questioned DCCR’s novelty (calling attention to generic diazoxide) and highlighted patient harm instances. The fact that Soleno’s CEO had to address this report’s impact on an earnings call (natlawreview.com) signals that Scorpion hit a nerve. While not all short-seller claims are accurate, their presence often indicates potential undisclosed issues. The market reaction – a sharp stock drop – and subsequent legal action imply that Scorpion’s claims resonated. Investors should monitor if any ongoing investigations (journalistic or regulatory) build on these allegations. Until Soleno can convincingly refute or mitigate Scorpion’s points, caution is warranted.
– Stock Volatility and Promotion vs. Reality: Soleno’s share price behavior has been extreme, which can be a red flag in itself. The stock soared from penny-stock levels to over $75 at one point in 2025 (natlawreview.com), then seesawed between $47–$68 after controversies (natlawreview.com) (natlawreview.com). Such volatility often correlates with hype-driven cycles. Indeed, Soleno’s rally was bolstered by very bullish analyst coverage (with lofty price targets) (finviz.com) and a compelling rare-disease story, whereas the subsequent plunge was triggered by negative revelations. This boom-bust pattern suggests that expectations might have run ahead of fundamentals. For example, Soleno’s underwriters and analysts promoted a vision of rapid uptake and safe use, which is now being tempered by real-world data showing uptake challenges and side effects. Investors should be alert to any disconnect between promotional messaging and actual performance. The accelerated $100 M buyback in November 2025 can be seen two ways: management showing confidence, or an attempt to prop up the stock price amid decline. In either case, it’s unusual for a first-year commercial biotech to shift from equity issuance to large buybacks within months – a sign that internal priorities might have changed due to stock pressure.
– Ongoing Legal and Governance Overhang: Until the class action and any related investigations are resolved, Soleno faces an overhang from possible governance lapses. The allegations imply that internal controls or ethics around disclosure may have failed, which is a red flag for corporate governance. Even the hint of “adverse regulatory action, reputational and legal fallout” being discussed in court filings is concerning (www.globenewswire.com). If evidence emerges that executives knew more about safety issues and withheld it, or made overly aggressive claims to boost the stock, that could result in management changes or stricter oversight. At minimum, the company may need to rebuild trust with the investor community. For a small company, diverting attention to fight lawsuits (or paying for settlements) can slow down operational momentum. Thus, investors should keep an eye on the progress of these legal cases as a barometer of management’s credibility.
In sum, Soleno has some warning signs – particularly around how it has navigated the transition from R&D to commercialization under intense scrutiny. High-growth biotechs often have growing pains, but Soleno’s involve questions of candor and sustainability that prudent investors will not want to gloss over.
Open Questions & Unresolved Issues
Looking ahead, there are several open questions that will determine Soleno’s trajectory in 2026 and beyond. Investors should consider these areas where clarity is still emerging:
– How Sustainable is VYKAT XR’s Growth? Soleno captured ~12% of the U.S. PWS patient population in 2025 (www.globenewswire.com). Can it continue penetrating the market at a high rate, or will growth level off as it reaches a saturation point? Key indicators will be quarterly new patient starts vs. discontinuations. An open question is whether the patients who have not yet started therapy are primarily those with milder PWS or greater concern about side effects – if so, they may be harder to convert. Sustaining momentum may require additional real-world data demonstrating long-term benefits of VYKAT XR (e.g. improved outcomes like weight control or quality of life) to convince more physicians and families to come on board.
– Can Safety Concerns be Mitigated or Managed? Now that thousands of doses of VYKAT XR have been administered, what will the long-term safety profile look like? Will the ~12% adverse-event discontinuation rate improve over time (for instance, as doctors learn to manage fluid retention with diuretics or dose adjustments), or could new severe side effects emerge with broader use? It’s also uncertain whether post-marketing studies or surveillance might uncover issues not seen in trials. How Soleno proactively addresses safety – through patient monitoring programs, updated labeling if needed, and physician education – will be crucial in maintaining trust. This ties into whether regulators (FDA or EMA) impose any further requirements; as of now, no REMS is publicly known, but that could change if adverse event trends worsen. Investors will be looking for updates from the company on safety data in each quarterly report.
– What is the Outcome of the Ongoing Litigation? The securities class action is in early stages, and Soleno has yet to publicly respond in detail to the allegations. An open question is whether any internal documents or communications (surfaced during legal discovery) will validate or refute the claims of intentional misrepresentation. The case could take years to resolve, but interim developments – like a motion to dismiss ruling or a class certification decision – might provide clues. Additionally, one wonders if Soleno will consider a settlement to put the issue to rest, and what financial or governance concessions that might entail. The May 5, 2026* lead plaintiff deadline (natlawreview.com) suggests we’ll know the composition of the shareholder plaintiffs soon; a strong lead plaintiff (e.g. an institutional investor) might intensify pressure on Soleno. While the lawsuit doesn’t directly impact daily operations, its resolution could affect Soleno’s financials (if a settlement payout is required) and reputation.
– European and International Expansion Plans: Soleno has submitted a Marketing Authorization Application (MAA) in Europe for DCCR and recently completed the Day-120 questions with the EMA (www.biospace.com). The timeline and likelihood of EU approval remain open questions. Typically, the EMA could render a decision by late 2026 or early 2027 given the review process. Investors will want to know: will Soleno receive EU approval on the first pass, and if so, will it commercialize alone or seek a partner? The company has hinted at pursuing regulatory nods “in other territories, starting with the EU” (www.globenewswire.com). Europe’s market size could rival the U.S., but launching there may require significant investment (salesforce, etc.) or a licensing deal. Other regions like Japan or Australia might follow. How Soleno handles ex-U.S. strategy – and the costs or partnerships involved – is a key unknown that could either unlock new growth or strain its resources.
– Pipeline Development and Use of Cash: With over a half-billion dollars in cash on hand, Soleno has the luxury (and shareholder expectation) of building a pipeline beyond PWS. The company has stated it will evaluate DCCR in additional high-need rare diseases (www.globenewswire.com). Which indications might these be? This is an open question: DCCR’s mechanism (modulating insulin and glucose regulation) could potentially target conditions like congenital hyperinsulinism, certain forms of obesity, or other metabolic syndromes. Investors are awaiting more detail on what new trials or studies Soleno might initiate. Similarly, will Soleno use its cash for acquisitions or in-licensing to diversify its portfolio? Thus far, management has not announced any new assets, but the possibility remains given their cash war chest. Another question is whether Soleno will continue to return capital to shareholders in 2026 (e.g. another buyback or even a future dividend if cash flow stays strong). The 2025 buyback was a surprise – how the company allocates capital going forward (growth vs. shareholder returns) remains to be seen.
– Competitive Landscape in PWS: Soleno currently enjoys first-mover advantage in treating hyperphagia in PWS, but will it last? We should ask what competing approaches are in development. For instance, are other biotech companies now accelerating PWS programs after Soleno’s success? There are known efforts using hormonal or genetic therapies for PWS (e.g. analogs of carbetocin or oxytocin for appetite, gene therapies targeting the underlying genetic defect) – none approved yet, but some in clinical trials. It’s an open question if any competitor could challenge VYKAT XR in efficacy or safety in the coming years. Additionally, could off-label use of existing drugs (like GLP-1 agonists for appetite suppression, or generic diazoxide in a DIY regimen) gain traction as alternatives? If any such approaches show promise, they might curtail Soleno’s market share. Investors will want to keep an eye on PWS research news and Soleno’s responses (e.g., lifecycle management like improved formulations or combination therapies to stay ahead).
Overall, while Soleno has achieved a major breakthrough with its product launch, many questions remain unanswered about its future path. The next 12–18 months should provide clarity on whether VYKAT XR’s early success can be parlayed into a durable franchise – or whether unforeseen challenges (be they safety, legal, competitive, or commercial) will alter the narrative. Given the urgency implied in the legal situation and volatile stock movements, SLNO investors would be wise to stay informed and vigilant as these open issues resolve.
Sources: The analysis above is grounded in Soleno’s official financial releases, SEC filings, and credible reports. Key information was drawn from Soleno’s Q3 and Q4 2025 earnings announcements (www.globenewswire.com) (www.globenewswire.com), the company’s December 2024 debt financing release (investors.soleno.life), and independent data on market valuation (finviz.com). Insights on risks and legal matters were supported by GlobeNewswire and legal press releases detailing the class action allegations (www.globenewswire.com) (natlawreview.com) and the aftermath of a short-seller investigation (natlawreview.com). All source references are included inline for verification and further reading.
For informational purposes only; not investment advice.